Operating
Non-cash interest expense on liabilities related to the sale of future royalties and development funding
Alnylam Pharmaceuticals Non-cash interest expense on liabilities related to the sale of future royalties and development funding remained flat by 0.0% to $59.6M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 87.5%, from $31.78M to $59.6M. Over 2 years (FY 2023 to FY 2025), Non-cash interest expense on liabilities related to the sale of future royalties and development funding shows an upward trend with a 49.6% CAGR.
Analysis
StatementCash Flow Statement
SectionOperating
First reportedQ1 2023
Last reportedQ4 2025Feb 12, 2026
Metric ID:
operating_non_cash_interest_expense_on_liabilities_relat_87ea61Historical Data
3 years
| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | $106.55M | $127.13M | $238.4M |
| YoY Change | — | +19.3% | +87.5% |
Range$106.55M – $238.4M
CAGR+49.6%
Avg YoY Growth+53.4%
Median YoY Growth+53.4%
Current Streak2+ years growth
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's non-cash interest expense on liabilities related to the sale of future royalties and development funding?
- Alnylam Pharmaceuticals (ALNY) reported non-cash interest expense on liabilities related to the sale of future royalties and development funding of $59.6M in Q4 2025.
- How has Alnylam Pharmaceuticals's non-cash interest expense on liabilities related to the sale of future royalties and development funding changed year-over-year?
- Alnylam Pharmaceuticals's non-cash interest expense on liabilities related to the sale of future royalties and development funding increased by 87.5% year-over-year, from $31.78M to $59.6M.
- What is the long-term trend for Alnylam Pharmaceuticals's non-cash interest expense on liabilities related to the sale of future royalties and development funding?
- Over 2 years (2023 to 2025), Alnylam Pharmaceuticals's non-cash interest expense on liabilities related to the sale of future royalties and development funding has grown at a 49.6% compound annual growth rate (CAGR), from $106.55M to $238.4M.